Fresenius Kabi spurts as overseas parent seeks voluntary delisting

Fresenius Kabi Oncology jumped 9.8% to Rs 139.50 at 11:40 IST on BSE after the company said it has received a letter from its foreign parent notifying its intention to delist the company's shares from the bourses.

The company made the announcement during trading hours today, 17 April 2013.

Meanwhile, the S&P BSE Sensex was up 65.11 points or 0.35% at 18,810.04.

The stock spurted on high volumes. On BSE, 8.06 lakh shares were traded in the counter as against average daily volume of 47,058 shares in the past one quarter.

The stock hit a high of Rs 152.45 and a low of Rs 126.20 so far during the day. The stock had hit a 52-week low of Rs 78.50 on 18 October 2012. The stock had hit a 52-week high of Rs 176 on 17 April 2012.

The stock had outperformed the market over the past one month till 16 April 2013, surging 10.53% compared with the Sensex's 3.51% fall. The scrip had also outperformed the market in past one quarter, jumping 23.77% as against Sensex's 5.41% fall.

The small-cap company has equity capital of Rs 15.82 crore. Face value per share is Re 1.

Fresenius Kabi Oncology during trading hours today, 17 April 2013, said it has received a letter dated 16 April 2013 from its foreign parent -- Fresenius Kabi (Singapore) Pte (FKSL) -- notifying the company of its intention to make a voluntary delisting offer to the public shareholders of the company to acquire the entire public shareholding of the company of 3.06 crore equity shares of Re 1 each, representing 19% of the share capital of the company and delist the equity shares of the company from the stock exchanges on which the equity shares of the company are presently listed, i.e., BSE and the National Stock Exchange of India in accordance with the SEBI (Delisting of Equity Shares) Regulations, 2009 (Delisting Offer).

Fresenius Kabi Oncology's net profit galloped 3354.3% to Rs 48.36 crore on 35.9% growth in net sales to Rs 150.38 crore in Q3 December 2012 over Q3 December 2011.

Fresenius Kabi Oncology is engaged in cancer research and development of anti-cancer products. The company manufactures active pharmaceutical ingredients (APIs), intermediates and oral & injectable finished dosage forms.

Powered by Capital Market - Live News